by Raynovich Rod | Nov 29, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotechnology Stocks Hits New Highs After A Choppy 60 Days Biotechnology stocks eked out small gains today taking the liquid $4.4B market cap ETF (IBB) to new highs at $225 up 5.58% for the week and 5.94% for the month of November.The $1B market cap ETF (XBI $130.49)...
by Raynovich Rod | Nov 25, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Up until recently the Fidelity Select Biotechnology Fund (FBIOX) has outperformed all ETFs but now the IBB and PBE are leaders over the last 3 months. There have been two recent mini-corrections but over the past two weeks the IBB has soared up almost 15% for the past...
by Raynovich Rod | Nov 22, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Large Cap Biotechs Rocketing Up:BIIB, GILD Despite a flattish Dow and S&P, many life science stocks are surging ahead. There are many movers in the Rayno Biopharmaceutical Portfolio : Biogen Idec BIIB $277) up 10%, Gilead (GILD $74.40) up 3.88% and Regeneron (REGN...
by Raynovich Rod | Nov 19, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Bull Market Intact But Momentum Stocks Taking Hits Most of you know the game. Buy stocks with headline news, new business models, increasing RSI and charts that scream momentum. Examples proliferate: Aegerion (AEGR), Celldex (CLDX), Netflix (NFLX), Tesla (TSLA), 3D...
by Raynovich Rod | Nov 15, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Vertex (VRTX $67) Contrarian Trade Working Vertex is one of the worse performing large cap biotechs over 6 mos. is getting boosted on a $152M royalty deal. “Risk-On “Mode in Biotech Stocks Biotech stocks continue to find buyers with the IBB ($211.70)...
by Raynovich Rod | Nov 11, 2013 | Biopharmaceuticals
Biotech Stocks Perk Up on Shire/ViroPharma Merger Sweet Spot of The Market- Mid-Caps With Sales Growth One of the core Rayno Biopharmaceutical stock picks is up 25% to $49.37 in a $4.2B deal. ViroPharma, Inc. is a rare disease drug Company whose commercial product...
by Raynovich Rod | Nov 6, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Strong Jobs Report Boosts Market–Treasuries Sell -Off with 10 Year up to 2.74% Volatile Week Finds Buyers-Technical Levels Hold 11/8/13 9:45 a Biotechnology stocks rebounded today with the IBB up 3% to $203.86. The sector hit a major downdraft yesterday but we...
by Raynovich Rod | Nov 5, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Remains Strong But Momentum Is Easing Biotechnology stocks were positive today but major ETFs mixed with the FBT ($63.82) off 1.45%. Profit taking has hit some high fliers (AEGR,INCY) and many of our portfolio stocks are off their recent highs. Small and...
by Raynovich Rod | Nov 4, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Updated 2/11/15 see chart below Rayno 2013 Picks Outperform Biotechnology Indices and Funds Biopharmaceutical stocks hit all time highs in 2013 with major ETFs up as follows YTD: FBT ($65) up 41%, IBB ($206) up 50%, and XBI ((%120) up 36%. The Five Star Fidelity...
by Raynovich Rod | Nov 1, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Equities: The Only Game in Town With Rates Under 3%? October, normally a month to be cautious on the market, proved that trends can be misleading even in the midst of turbulent times in Washington. DOW Up 2.5%, S&P Up 3.5%, NASDAQ Up 2.5%. Healthcare stocks...
